ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1594

Bone Turnover Markers in Adults with Systemic Lupus Erythematosus

Aliese Sarkissian1, Vidya Sivaraman2, Sharon Bout-Tabaku3, Stacy P. Ardoin4, Melissa Moore-Clingenpeel5, Holly Steigelman6, Kelly Morris7 and Sasigarn Bowden8, 1Pediatric Rheumatology, Nationwide Children's Hosptial and The Ohio State University Medical Center, Columbus, OH, 2Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, 3Rheumatology, Nationwide Children's Hospital, Columbus, OH, 4Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 5Research, Nationwide Children's Hospital, Dublin, OH, 6The Ohio State University Wexner Medical Center, Columbus, OH, 7Rheumatology and Immunology, The Ohio State University, Columbus, OH, 8Pediatric Endocrinology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Bone turnover markers and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic inflammatory disease which has an increased risk for comorbid osteoporosis, related to the disease and long term corticosteroid therapy. Bone turnover markers (BTMs) reflect the process of bone formation and resorption; imbalances in this process are associated with bone loss and osteoporosis. Changes in BTMs have been observed in SLE patients with conflicting results. This study examined the association between BTMs and their relationship to disease activity.

Methods: SLE patients were identified from a university research registry and biorepository of patients with rheumatic disease. Demographics, disease activity, medication use and laboratory data were collected. Serum was assayed for C-terminal telopeptide of type 1 collagen (CTX), a bone resorption marker, and osteocalcin (OC), a bone formation marker. Serum CTX index, expressed as a ratio of measured CTX value to upper limit of normal value for age and gender, was used for analysis. The patients were stratified by SLE disease activity index (SLEDAI): a score of <3 (low disease activity) and ≥3 (higher disease activity). We analyzed correlations between BTMs and variables that have known associations.

Results: Serum levels of BTMs were measured in 42 subjects of which 88% were white females with a median age of 36 years, and 19% had lupus nephritis or chronic kidney disease. Most were on ongoing corticosteroid treatment (68%) and 47% were on vitamin D supplementation. Only 36% had a serum vitamin D level >30 ng/mL and 32% were insufficient (20-30 ng/mL) and 32% were deficient (<20 ng/mL). The median OC value was 13.5 ng/mL (normal 9-42), and the median CTX index was 0.54. Subjects with a higher SLEDAI score had lower median OC level compared to those with low SLEDAI score (median [IQR] of 11 [10, 16] vs. 18 [13, 22], p=0.02). There were no significant differences in CTX between these two groups. There was a positive correlation between the CTX index and OC (r = 0.537, p<0.01).

Conclusion: SLE patients with higher disease activity had lower OC levels than in those with low disease activity, suggesting that inflammation may suppress bone formation. There was no difference in CTX index between patients with higher and low disease activity. Bone formation and resorption markers were positively correlated in our SLE cohort, suggesting a coupled bone turnover state. The next step is to determine if corticosteroid dosage plays a role in the decreased bone formation observed in this cohort.


Disclosure: A. Sarkissian, None; V. Sivaraman, None; S. Bout-Tabaku, None; S. P. Ardoin, None; M. Moore-Clingenpeel, None; H. Steigelman, None; K. Morris, None; S. Bowden, None.

To cite this abstract in AMA style:

Sarkissian A, Sivaraman V, Bout-Tabaku S, Ardoin SP, Moore-Clingenpeel M, Steigelman H, Morris K, Bowden S. Bone Turnover Markers in Adults with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/bone-turnover-markers-in-adults-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-turnover-markers-in-adults-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology